IndustryCompany release

Jasper Therapeutics sets 1-for-30 reverse stock split from 6 November

🇺🇸 Jasper Therapeutics, Inc. (JSPR) · Wed 04 Nov 2026

The clinical-stage immune disease biotech says the share consolidation, aimed at regaining Nasdaq bid-price compliance, will cut shares outstanding from about 33.3 million to about 1.11 million.

Jasper Therapeutics, a clinical-stage biotech focused on immune diseases and listed on Nasdaq under the ticker JSPR, has announced a 1-for-30 reverse split of its common stock. Split-adjusted trading on the Nasdaq Capital Market is due to begin on 6 November 2026.

Once the split takes effect, the number of shares outstanding will fall from roughly 33.3 million to roughly 1.11 million. The company links the move to its efforts to regain compliance with Nasdaq's minimum bid price requirement.

The timeline of approvals is as follows: stockholders backed the split on 30 September, and the board then fixed the 1-for-30 ratio on 23 October. The company's announcement is dated 4 November 2026.

No further details, such as treatment of fractional shares or the status of the company's clinical programmes, were available in the material on file.

What it means for your team

  • The split is a corporate and listing measure; the material on file does not mention any change to Jasper's clinical or regulatory plans.
  • Teams tracking Jasper as a partner, sponsor or supplier may see financial-data and ticker records updated to reflect split-adjusted share counts from 6 November.
  • Reverse splits aimed at bid-price compliance are a common tool for small-cap biotechs, and can signal funding or listing pressure worth monitoring in counterparty risk reviews.

Company's press release (SEC filing): Jasper Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Jasper Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →